FDA Approves Adhansia XR
The Carlat Child Psychiatry Report, Volume 10, Number 4&5, May 2019
Talia Puzantian, PharmD, BCPP
Joshua Feder, MD
Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.